Precision Medicine

Medical experts discuss bispecific antibody utilization in the management of non-Hodgkin lymphoma (NHL).

Jamie Koprivnikar, MD, and Solly Chedid, MD, provide insights surrounding treatment management for patients diagnosed with lower-risk MDS.

Experts on hematologic malignancies have a comprehensive discussion on chronic graft-versus-host disease, focusing on clinical trial data, treatment practices, and the evolving therapeutic landscape.

Matthew Campbell, MD, MS, and Rana McKay, MD, provide a comprehensive overview of current treatment strategies, analyze long-term data from pivotal clinical trials, and explore ongoing challenges in clear cell renal cell carcinoma.

Medical oncologists specializing in breast cancer have a comprehensive discussion on the evolving treatment landscapes for HER2-negative and HER2-low metastatic breast cancer, focusing on ADC-directed therapies.

Rebecca A. Shatsky, MD, an expert on breast cancer, offers comprehensive insights on HER2-targeting therapies, highlighting treatment practices, clinical trial data, and exciting developments in the therapeutic space.

Experts on lung cancer discuss treatment strategies in early non-small cell lung cancer and the role of immunotherapy.

Explore the latest insights on Ruxolitinib in Steroid Refractory Chronic GvHD, as two experts share their perspectives on advancements and considerations in the field.

Experts on myelodysplastic syndrome provide comprehensive insights on the evolving disease and treatment landscape.

Anne S.Tsao, MD, and Edward B. Garon, MD, MS, review clinical trial data and discuss the evolving role of antibody-drug conjugates and TROP2-directed therapies in the treatment of patients with non–small cell lung cancer.

Key opinion leaders share an enlightening discussion about the latest updates in precision medicine for gastrointestinal malignancies, offering valuable insights for healthcare professionals and patients alike.

Experts David Morris, MD, FACS, and Benjamin Garmezy, MD, share insights about how they work together to offer multidisciplinary care for patients with advanced prostate cancer and discuss their current treatment approaches.

Expert oncologists discuss the evolving treatment paradigm of TROP2-directed antibody drug conjugates in patients with metastatic non-small cell lung cancer.

Michael Savona, MD and Amer Zeidan, MBBS provide an overview of myelodysplastic syndrome (MDS) and discuss emergent data and treatment updates for patients with lower-risk MDS.

Robert Motzer, MD, Elizabeth Plimack, MD, MS, and Brian Rini, MD discuss recent treatment updates for patients with advanced renal cell carcinoma (RCC) and their implications for the RCC treatment landscape and clinical practice.

On the role of CEACAM5 in the growth and progression of NSCLC, including the mechanism of action, current safety and efficacy data, and results from from recent trials.

Expert hematologist-oncologists share insight on the evolving role of XPO1 inhibitor therapy in the management of multiple myeloma and myelofibrosis.

Mark Socinski, MD, and Joshua Sabari, MD, discuss the treatment options for patients with KRASG12C mutated NSCLC with CNS metastases, and share advice for community oncologists treating this population.

Two expert hematologist-oncologists review treatment options for patients with follicular lymphoma and consider how to select the appropriate therapy based on patient and disease factors.

Expert hematologist-oncologists review treatment options for patients with myeloproliferative neoplasms and consider patient and disease factors that inform the selection of optimal therapy.

Hetty Carraway, MD, and Eytan M. Stein, MD, discuss treatment options for patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, and how to select the best treatment regimen based on patient and disease factors.

Expert hematologist/oncologists highlight recent advances in the treatment of advanced RCC and consider their impact on clinical practice.

Hetty Carraway, MD, and Eytan Stein, MD, discuss the frontline treatment options for patients with AML and how to select the best treatment approach based on patient and disease factors.

Shaji Kumar, MD, and Jonathan Kaufman, MD, discuss the role of BCL-2 proteins in multiple myeloma treatment and recent safety and efficacy data on BCL-2 inhibitors.

Two leading experts in lung cancer provide insights on therapies targeting ALK mutations patients with non-small-cell lung cancer.

Reactions to recent data on the integration of CD19-targeted therapies into the treatment of patients with diffuse large B-cell lymphoma.

John DiPersio, MD, PhD, and Michael Bishop, MD, review the use of JAK inhibitors in chronic GvHD and practical considerations for disease management.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss and compare BTK inhibitors used as targeted therapy for B-cell malignancies, taking into account data from clinical trials and their personal experiences.

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, discuss the importance of CD19-targeted therapy as a promising option in the relapsed/refractory DLBCL setting.

Future implications for palliative therapy with selective immunomodulating microtubule binding agents as prevention against chemotherapy-induced neutropenia in high-risk patients with solid tumors.